论文部分内容阅读
目的：比较人白细胞干扰素（ＬＩＦＮ）和基因工程干扰素α－１ｂ（ｒＩＦＮα－１ｂ）治疗慢性乙型肝炎（ＣＨＢ）的疗效和不良反应。方法：ＣＨＢ病人８３例（男性６９例，女性１４例；年龄３２±ｓ８ａ）。Ａ组２９例，用ＬＩＦＮ３ＭＵ；Ｂ组２７例，用ｒＩＦＮα－１ｂ３ＭＵ，Ｃ组２７例用人血浆白蛋白冻干制品１０ｇ，３组均ｉｍ，ｑｄ×４ｗｋ，继以ｑｏｄ×８ｗｋ。结果：３组ＨＢｅＡｇ阴转率分别为３８％，４１％，７％；ＨＢＶ－ＤＮＡ阴转率分别为４０％，５２％，７％。Ａ和Ｂ组ＩＦＮ对ＨＢＶ复制的抑制作用显著优于Ｃ组（Ｐ＜０．０５），但Ａ和Ｂ组间无显著差异。Ａ组不良反应显著大于Ｂ组（Ｐ＜０．０５）。结论：２种不同来源的ＩＦＮ治疗ＣＨＢ均有显著疗效，２药无显著差别，但Ａ组不良反应明显。
OBJECTIVE: To compare the efficacy and adverse effects of interleukin-17 (IFN-γ) and genetically engineered interferon alpha-1b (rIFNα-1b) in the treatment of chronic hepatitis B (CHB). Methods: 83 CHB patients (69 males and 14 females; age 32 ± s8a). A group of 29 cases with LIFN3MU; B group of 27 cases with rIFNα-1b3MU, C group 27 cases with human plasma albumin lyophilized product 10g, 3 groups were im, qd × 4wk, followed by qod × 8wk. Results: The negative conversion rates of HBeAg in 38%, 41%, and 7% of the three groups were 40%, 52% and 7%, respectively. The inhibitory effects of IFN on HBV replication in A and B groups were significantly better than those in C group (P <0.05), but there was no significant difference between A and B groups. Adverse reactions in group A were significantly greater than those in group B (P <0.05). Conclusion: Two different sources of IFN treatment of CHB have a significant effect, no significant difference between the two drugs, but A group of adverse reactions was significant.